Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600724 · ClinicalTrials.gov registry record · NA
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
A NA study of Diabetic Foot Ulcer and Diabetic Foot, sponsored by MiMedx Group.
- Recruiting
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT06600724: Recruiting NA study of Diabetic Foot Ulcer and Diabetic Foot, sponsored by MiMedx Group.
NCT06600724 is a NA study of Diabetic Foot Ulcer and Diabetic Foot that is actively recruiting participants, run by MiMedx Group. The registered enrollment target is 170 participants, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06600724, a NA study of Diabetic Foot Ulcer and Diabetic Foot, is actively recruiting participants, sponsored by MiMedx Group.
- RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
Primary Outcome
The percentage of target ulcers achieving complete wound closure in 12 weeks.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER EPIEFFECT
- OTHER EPIXPRESS
Study Locations (1)
Pennsylvania
- SerenaGroup - Monroeville - Monroeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06600724 shows while recruiting
NCT06600724 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (33% lower).
The record links to 5 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT06600724 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06600724 about?
NCT06600724 is a clinical study titled "Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs". This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
What is the current status of trial NCT06600724?
This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2024-08-27. Estimated completion is 2026-08.
What conditions does trial NCT06600724 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer, Foot Ulcer, Diabetic, Foot Ulcer Due to Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT06600724?
The interventions under investigation include: Standard of Care (OTHER), EPIEFFECT (OTHER), EPIXPRESS (OTHER).
Who is sponsoring clinical trial NCT06600724?
This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600724 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06600724's enrollment target sits among peer trials
170 22nd of 67 higher than 44 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
-
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI